Compare TOMZ & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | PHIO |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 14.6M |
| IPO Year | 2009 | 2011 |
| Metric | TOMZ | PHIO |
|---|---|---|
| Price | $0.59 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $10.67 |
| AVG Volume (30 Days) | 217.6K | ★ 562.0K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,738,842.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $68.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.23 | N/A |
| 52 Week Low | $0.54 | $0.81 |
| 52 Week High | $1.20 | $4.19 |
| Indicator | TOMZ | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.03 | 53.41 |
| Support Level | $0.54 | $1.01 |
| Resistance Level | $0.81 | $1.43 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 47.32 | 77.56 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.